The legislation in place today for regulating in silico products actually predates the existence of these technologies. In order for the in silco market to grow and for research in this field to be encouraged, a policy framework for in silico medicine needs to be developed. Just as the internet has created an urgent need to reform how we think about issues such as data security and IPR, in silico medicine requires we reevaluate our existing health policy structures. 

Even the most advanced and predictive model has little value to industry if it cannot be submitted as evidence of the effectiveness or safety of their product:

  • Manufacturers of medical devices who use in silico technologies must be provided with a framework for submitting this data to notified bodies, health authorities and evaluators of health technologies. 
  • Similarly for pharmaceuticals, a framework for admissibility of in silico clinical trial data needs to be developed so that we can move from exploratory clinical trials in humans, to a scenario where we seek to confirm what we know from in silico methods. 

 Incentives in policy need to be provided for industries that pioneer this research which has the potentially to drastically decrease overall research costs and greatly improve patient safety. Providing a system for assessing modelling and simulation data that supplement efficacy or safety data is required to bring healthcare into the digital era. 

“If healthcare is to move into the digital era, we need new policies that will enable this transition”

Avicenna Alliance news

The Avicenna Alliance co-organises a public workshop at the FDA on good simulation practices in health technologies

The Avicenna Alliance, the Medical Device Innovation Consortium (MDIC) and the...

find out more ›

The Avicenna Alliance nominated as a member of the European Commission's "eHealth Stakeholder Group"

On 3 February, Thierry Marchal, Secretary-General of the Avicenna Alliance has been informed that...

find out more ›

Avicenna Alliance puts forward questions to EU Expert Panel on effective ways of investing in health

On 17 December the European Commission launched a survey inviting stakeholders to put forward...

find out more ›

Show all activites

Sign up for our monthly newsletter!


Sign up